Skip to main content

RA Capital Healthcare Fund LP's Form 4 filing

Vor Biopharma Inc. (VOR) · filed Aug 26, 2026

Accession no.
0001231919-26-001102
Filed
Aug 26, 2026, 6:28 PM ET
Trade date
Aug 24, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
RA Capital Healthcare Fund LPCIK 000131508210% Owner
Ra Capital Management, L.P.CIK 000134682410% Owner
Kolchinsky PeterCIK 000138485910% Owner
Shah Rajeev M.CIK 000161984110% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 24, 2026Common StockMOption exerciseAcquired+1,500$3.74F1+$5,6041,500Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 24, 2026Common StockMOption exerciseDisposed−1,500$0.00$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The exercise price and number of shares underlying the stock option give effect to the reverse stock split.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)